Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone is a synthetic small molecule peptide derivative with the sequence Ac-Ala-Phe-EtCl. It contains an acetylated alanine, a phenylalanine residue, and a terminal chloroethyl ketone group. The compound is listed as experimental and has not been approved for any therapeutic use. There are no known clinical indications or trials reported for this molecule, and its mechanism of action has not been described in public databases[1][2]. No information on pharmacological activity or specific biological targets is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S) N-acetyl-L-alanyl-αL-phenylalanyl-chloroethylketone.